Previous Close | 216.57 |
Open | 216.74 |
Bid | 217.98 x 800 |
Ask | 218.05 x 800 |
Day's Range | 215.64 - 218.39 |
52 Week Range | 179.59 - 234.09 |
Volume | |
Avg. Volume | 743,178 |
Market Cap | 18.357B |
Beta (5Y Monthly) | 1.00 |
PE Ratio (TTM) | 50.41 |
EPS (TTM) | 4.33 |
Earnings Date | Apr 25, 2024 |
Forward Dividend & Yield | 2.88 (1.33%) |
Ex-Dividend Date | Feb 26, 2024 |
1y Target Est | 246.80 |
Subscribe to Yahoo Finance Plus to view Fair Value for LH
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health.
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2024 before the market opens on Thursday, April 25, 2024. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.
Labcorp's (LH) pTau217 test is a pivotal blood biomarker intended to aid in the diagnosis of Alzheimer's disease.